BLACK DIAMOND THERAPEUTICS, INC. Research and Development Expense
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Research and Development Expense of $7.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $7.39M, a 20.67% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $7.00M, a 33.34% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $6.30M, a 48.80% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $7.44M, a 42.41% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. research and development expense for fiscal 2025 was $33.56M, a 34.60% decline from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. research and development expense for fiscal 2024 was $51.31M, a 13.54% decline from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. research and development expense for fiscal 2023 was $59.35M, a 7.89% decline from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. research and development expense for fiscal 2022 was $64.44M, a 33.45% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.39M 10-Q · filed 2026-08-05 | $14.40M 10-Q · filed 2026-08-05 | $20.69M derived: sum of 3 quarters · filed 2026-08-05 | $28.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $7.00M 10-Q · filed 2026-05-07 | $13.30M derived: sum of 2 quarters · filed 2026-05-07 | $20.74M derived: sum of 3 quarters · filed 2026-05-07 | $30.05M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $13.73M derived: sum of 2 quarters · filed 2026-03-16 | $23.05M derived: sum of 3 quarters · filed 2026-08-05 | $33.56M 10-K · filed 2026-03-16 |
| 2025-09-30 | $7.44M 10-Q · filed 2025-11-06 | $16.76M derived: sum of 2 quarters · filed 2026-08-05 | $27.26M 10-Q · filed 2025-11-06 | $39.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $9.32M 10-Q · filed 2026-08-05 | $19.82M 10-Q · filed 2026-08-05 | $32.12M derived: sum of 3 quarters · filed 2026-08-05 | $45.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $10.51M 10-Q · filed 2026-05-07 | $22.80M derived: sum of 2 quarters · filed 2026-05-07 | $35.72M derived: sum of 3 quarters · filed 2026-05-07 | $48.27M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $25.21M derived: sum of 2 quarters · filed 2026-03-16 | $37.77M derived: sum of 3 quarters · filed 2026-03-16 | $51.31M 10-K · filed 2026-03-16 |
| 2024-09-30 | $12.91M 10-Q · filed 2025-11-06 | $25.47M derived: sum of 2 quarters · filed 2025-11-06 | $39.02M 10-Q · filed 2025-11-06 | $54.30M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $12.56M 10-Q · filed 2025-08-07 | $26.10M 10-Q · filed 2025-08-07 | $41.39M derived: sum of 3 quarters · filed 2025-08-07 | $57.54M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $13.54M 10-Q · filed 2025-05-12 | $28.83M derived: sum of 2 quarters · filed 2025-05-12 | $44.99M derived: sum of 3 quarters · filed 2025-05-12 | $58.14M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $15.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $31.44M derived: sum of 2 quarters · filed 2025-03-06 | $44.60M derived: sum of 3 quarters · filed 2025-03-06 | $59.35M 10-K · filed 2025-03-06 |
| 2023-09-30 | $16.15M 10-Q · filed 2024-11-05 | $29.31M derived: sum of 2 quarters · filed 2024-11-05 | $44.06M 10-Q · filed 2024-11-05 | $58.67M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $13.15M 10-Q · filed 2024-08-06 | $27.91M 10-Q · filed 2024-08-06 | $42.52M derived: sum of 3 quarters · filed 2024-08-06 | $58.36M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $14.75M 10-Q · filed 2024-05-09 | $29.36M derived: sum of 2 quarters · filed 2024-05-09 | $45.21M derived: sum of 3 quarters · filed 2024-05-09 | $61.40M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $14.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $30.46M derived: sum of 2 quarters · filed 2024-03-12 | $46.65M derived: sum of 3 quarters · filed 2024-03-12 | $64.44M 10-K · filed 2024-03-12 |
| 2022-09-30 | $15.85M 10-Q · filed 2023-11-06 | $32.04M derived: sum of 2 quarters · filed 2023-11-06 | $49.83M 10-Q · filed 2023-11-06 | $69.49M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $16.20M 10-Q · filed 2023-08-11 | $33.98M 10-Q · filed 2023-08-11 | $53.65M derived: sum of 3 quarters · filed 2023-08-11 | $81.27M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $17.79M 10-Q · filed 2023-05-09 | $37.45M derived: sum of 2 quarters · filed 2023-05-09 | $65.08M derived: sum of 3 quarters · filed 2023-05-09 | $91.80M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $19.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $47.29M derived: sum of 2 quarters · filed 2023-03-09 | $74.01M derived: sum of 3 quarters · filed 2023-03-09 | $96.83M 10-K · filed 2023-03-09 |
| 2021-09-30 | $27.63M 10-Q · filed 2022-11-08 | $54.34M derived: sum of 2 quarters · filed 2022-11-08 | $77.17M 10-Q · filed 2022-11-08 | $94.92M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $26.72M 10-Q · filed 2022-08-09 | $49.54M 10-Q · filed 2022-08-09 | $67.30M derived: sum of 3 quarters · filed 2022-08-09 | $80.22M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $22.82M 10-Q · filed 2022-05-11 | $40.58M derived: sum of 2 quarters · filed 2022-05-11 | $53.51M derived: sum of 3 quarters · filed 2022-05-11 | $63.67M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $17.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $30.68M derived: sum of 2 quarters · filed 2022-03-17 | $40.85M derived: sum of 3 quarters · filed 2022-03-17 | $48.21M 10-K · filed 2022-03-17 |
| 2020-09-30 | $12.93M 10-Q · filed 2021-11-08 | $23.10M derived: sum of 2 quarters · filed 2021-11-08 | $30.45M 10-Q · filed 2021-11-08 | $37.91M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $10.17M 10-Q · filed 2021-08-12 | $17.52M 10-Q · filed 2021-08-12 | $24.98M derived: sum of 3 quarters · filed 2021-08-12 | $30.62M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $7.35M 10-Q · filed 2021-05-07 | $14.81M derived: sum of 2 quarters · filed 2021-05-07 | $20.45M derived: sum of 3 quarters · filed 2021-05-07 | $26.09M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $7.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $13.09M derived: sum of 2 quarters · filed 2021-03-25 | $18.74M derived: sum of 3 quarters · filed 2021-03-25 | $21.75M 10-K · filed 2021-03-25 |
| 2019-09-30 | $5.63M 10-Q · filed 2020-11-10 | $11.28M derived: sum of 2 quarters · filed 2020-11-10 | $14.29M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $5.65M 10-Q · filed 2020-08-11 | $8.66M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $3.01M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $6.95M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |